ATC Group: L04AB02 Infliximab

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L04AB02 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L04 Immunosuppressants
3 L04A Immunosuppressants
4 L04AB Tumor necrosis factor alpha (TNF-α) inhibitors
5 L04AB02 Infliximab

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
PAREN - Parenteral 3.75 mg

Active ingredients in L04AB02

Active Ingredient Description
Infliximab

Infliximab is a chimeric human-murine monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNFα but not to lymphotoxin α (TNFβ).

Related product monographs

Title Information Source Document Type  
AVSOLA Powder for solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
FLIXABI Powder for concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC
INFLECTRA Powder for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC
RENFLEXIS Powder for solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
ZESSLY Powder for concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Albania (AL)

Ecuador (EC)

Hong Kong (HK)

Israel (IL)

Japan (JP)

New Zealand (NZ)

Singapore (SG)

South Africa (ZA)

Tunisia (TN)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.